BRIEF-Merck receives breakthrough therapy designation from FDA for use of Keytruda in classical hodgkin lymphoma
April 18, 2016 at 08:16 AM EDT
April 18 (Reuters) - Merck Says Fourth Designation For Keytruda Follows Breakthrough Status In Advanced Melanoma, Non
